HC Wainwright Predicts Vivani Medical Q1 Earnings

Vivani Medical, Inc. (NASDAQ:VANI) – Equities researchers at HC Wainwright issued their Q1 2027 earnings per share estimates for shares of Vivani Medical in a research note issued on Thursday, July 9th. HC Wainwright analyst Y. Chen forecasts that the company will post earnings of ($0.07) per share for the quarter. HC Wainwright has a “Buy” rating and a $3.50 price objective on the stock. The consensus estimate for Vivani Medical’s current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for Vivani Medical’s Q2 2027 earnings at ($0.07) EPS, Q3 2027 earnings at ($0.07) EPS, Q4 2027 earnings at ($0.06) EPS and FY2027 earnings at ($0.27) EPS.

VANI has been the topic of several other reports. Lake Street Capital initiated coverage on shares of Vivani Medical in a report on Tuesday, June 23rd. They set a “buy” rating and a $4.00 price target on the stock. Weiss Ratings upgraded Vivani Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Vivani Medical currently has a consensus rating of “Hold” and an average target price of $3.75.

Vivani Medical Stock Performance

Vivani Medical stock opened at $1.56 on Friday. Vivani Medical has a twelve month low of $0.92 and a twelve month high of $1.92. The firm has a market cap of $134.53 million, a PE ratio of -3.90 and a beta of 2.33. The firm’s 50 day moving average price is $1.22 and its two-hundred day moving average price is $1.24.

Vivani Medical (NASDAQ:VANI) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08).

Insider Buying and Selling

In related news, Director Gregg Williams bought 1,587,301 shares of the business’s stock in a transaction on Monday, June 15th. The shares were bought at an average cost of $1.26 per share, for a total transaction of $1,999,999.26. Following the completion of the acquisition, the director directly owned 36,119,086 shares in the company, valued at approximately $45,510,048.36. This represents a 4.60% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have acquired 4,761,903 shares of company stock worth $5,999,998 over the last 90 days. Corporate insiders own 53.30% of the company’s stock.

Institutional Investors Weigh In On Vivani Medical

Several institutional investors and hedge funds have recently added to or reduced their stakes in VANI. Citadel Advisors LLC bought a new stake in Vivani Medical during the third quarter worth approximately $26,000. Susquehanna International Group LLP grew its holdings in Vivani Medical by 100.5% in the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock valued at $46,000 after buying an additional 16,200 shares during the last quarter. Jane Street Group LLC bought a new position in Vivani Medical in the 4th quarter worth approximately $60,000. Renaissance Technologies LLC increased its position in Vivani Medical by 118.4% in the 4th quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock worth $121,000 after buying an additional 53,127 shares during the period. Finally, Marshall Wace LLP acquired a new position in shares of Vivani Medical during the fourth quarter worth approximately $174,000. 6.78% of the stock is currently owned by institutional investors and hedge funds.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.